tradingkey.logo

Oxygen concentrator maker Inogen's prelim Q4 revenue grows 2% on strong B2B performance

ReutersJan 12, 2026 1:41 PM


Overview

  • Medical technology firm's preliminary Q4 revenue grew 2%

  • Company expects positive Adjusted EBITDA for full yr 2025


Outlook

  • Company to provide 2026 financial guidance during February earnings call


Result Drivers

  • ORDER TIMING SHIFT - Q4 revenue impacted by delay in large customer orders to 2026, per CEO Kevin Smith

  • B2B CHANNELS - Strong performance in business-to-business channels contributed to Q4 results


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Miss

$82 mln

$88.60 mln (2 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Inogen Inc is $13.00, about 84.9% above its January 9 closing price of $7.03

Press Release: ID:nBw4jRZVda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI